Yoo Jinyoung, Park Sonya Y, Robinson Robert A, Kang Seok Jin, Ahn Woong Shick, Kang Chang Suk
Department of Pathology, St Vincent's Hospital, Catholic University, Suwon, Kyungkido, South Korea.
Arch Pathol Lab Med. 2002 Sep;126(9):1096-100. doi: 10.5858/2002-126-1096-RGMAEO.
To investigate ras gene alteration in human gastric adenocarcinomas and its potential relationship to ras signal transduction mediators.
Genomic DNA from 104 gastric tumors were analyzed by sequencing of polymerase chain reaction-amplified products for the presence of ras mutations. All the samples were further investigated with the use of immunohistochemical analysis for ERK1 and ERK2.
Tertiary care teaching hospital.
Seventy patients from a Korean population and 34 from a Midwestern US population composed of white Americans and African Americans.
Fifteen tumors (14%) were positive for either H-ras or K-ras mutation: 9 (13%) of 70 Korean patients and 6 (18%) of 34 US patients. Seven (78%) of the 9 mutated tumors from Korean patients and all 6 (100%) from the US patients were intestinal-type lesions. Either ERK1 and/or ERK2 was overexpressed in 68 samples (65%). No association was established between ras mutations and overexpression of ERK1/2. However, the correlation between ERK1/2 and progression (early vs late) was statistically significant (P =.007).
These data suggest that ras mutations are uncommon in gastric adenocarcinomas and that differing racial and/or geographic mechanisms may not underlie ras gene alteration. Most ras mutations were, however, observed in the group of intestinal-type samples, supporting the different genetic mechanisms of carcinogenesis between the intestinal- and diffuse-type tumors. It is noteworthy that enhanced ERK1/2 activity could be one of the characteristics of tumor invasiveness in gastric cancers.
研究人类胃腺癌中的ras基因改变及其与ras信号转导介质的潜在关系。
通过对聚合酶链反应扩增产物进行测序,分析104例胃肿瘤的基因组DNA中是否存在ras突变。所有样本均进一步采用免疫组织化学分析法检测ERK1和ERK2。
三级医疗教学医院。
70例韩国患者和34例来自美国中西部的患者,后者包括美国白人和非裔美国人。
15例肿瘤(14%)的H-ras或K-ras突变呈阳性:70例韩国患者中有9例(13%),34例美国患者中有6例(18%)。韩国患者的9例突变肿瘤中有7例(78%),美国患者的所有6例(100%)均为肠型病变。68个样本(65%)中ERK1和/或ERK2过表达。ras突变与ERK1/2过表达之间未发现关联。然而,ERK1/2与疾病进展(早期与晚期)之间的相关性具有统计学意义(P = 0.007)。
这些数据表明,ras突变在胃腺癌中并不常见,不同种族和/或地理机制可能不是ras基因改变的基础。然而,大多数ras突变见于肠型样本组,支持肠型和弥漫型肿瘤之间不同的致癌遗传机制。值得注意的是,ERK1/2活性增强可能是胃癌肿瘤侵袭性的特征之一。